LncRNA MALAT1 Suppression Protects Endothelium against oxLDL-Induced Inflammation via Inhibiting Expression of MiR-181b Target Gene TOX

Figure 2

MALAT1 and miR-181b expression in AS patients and oxLDL-treated HUVECs. (a, b) Levels of circulating lncRNA MALAT1 and miR-181b in healthy volunteers and AS patients measured by RT-PCR. versus the control group. (c–h) Relative expression of MALAT1, miR-181b, and TOX about 24 h after treating with various concentrations of oxLDL (0, 50, 100, 150, and 200 μg/ml) or treating with oxLDL (150 μg/ml) for different times. versus the control group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)